Eye Vitamins: Part 6 – What’s all the talk about zinc? Page 4 NEW

2018 We’re here!

This is just one page in a series that talks about the path that started  when the results of the first AREDS research study was released in 2001 and continues in this most recent research.  There’s a lot to tell and I’m not yet done!

In January the Proceedings of the National Academy of Sciences (PNAS) released a new research paper by Vavvas and colleagues titled CFH and ARMS2 genetic risk determines progression to neovascular age-related macular degeneration after antioxidant and zinc supplementation.  

The researchers analyzed data from 802 patients (299 of those not analyzed in prior publications) who had been treated with either the AREDS formulation or a placebo in the original 2001 study. They were all people who started with intermediate dry AMD. Their analyses showed that variations in CFH and ARMS2 definitely affect an individual’s response to the AREDS formulation.  Specifically:

  • Approximately 40% of patients in the study had a 50% reduction in risk of progression from intermediate to advanced AMD, which was double the benefit shown in the 2001 AREDS publication.
  • 15% of patients with a specific combination of genetic risk variants nearly tripled their risk of developing wet AMD when treated with the AREDS formulation instead of a placebo.

Regarding any conflict of interest, neither the first author nor two co-authors have any conflicts of interest related to Arctic, the NEI or to the topic of the research. For more about the team, click here.

The analysis of over these AREDS patients, all with initial intermediate dry AMD, confirms the following:

  1.  The AREDS formulation impacts progression only to wet AMD, and not to geographic atrophy.
  2. There is a statistically significant interaction:
    • between CFH and ARMS2 genotype groups
    • treatment with the AREDS formulation
    • and progression to wet AMD.
  3. There is a group of people (high CFH and no ARMS2 risk which is C2A0) whose risk of developing wet AMD is almost tripled if treated with the AREDS formulation. This group constitutes about 15% of the population.

What does that mean to ME?

 


press release Jan. 18th Harvard Medical School New study shows strong interaction between genetics and nutritional supplement treatment on progression to neovascular age-related macular degeneration (AMD)

Ratings

  • Rate this
  • Summary
Current Average Ratings
Overall quality
Avg: 0/5
Applies to topic
Avg: 0/5
Helpful to me
Avg: 0/5
Eye Vitamins: Part 6 – What’s all the talk about zinc? Page 4 NEW
Total Avg Rating: 0.00 out of 5 with based on 0 rating(s)
Overall quality
Applies to topic
Helpful to me